Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
APS | Toronto | CAD | Real-time | |
APTO | NASDAQ | USD | Real-time | |
APS | CBOE Canada | CAD | Real-time |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Denis R. Burger | 79 | 2007 | Lead Independent Director |
Mark David Vincent | 70 | 2007 | Independent Director |
Warren Whitehead | 71 | 2011 | Independent Director |
Stephen B. Howell | 78 | - | Member of Scientific Advisory Board |
Brian J. Druker | 67 | 2013 | Chairman of Scientific Advisory Board |
Erich M. Platzer | 73 | 2014 | Independent Director |
Daniel Douglas Von Hoff | 75 | 2013 | Member of Scientific Advisory Board |
Michael Andreeff | - | 2015 | Member of Scientific Advisory Board |
Carol Gail Ashe | 65 | 2018 | Independent Director |
Bernd Robert Seizinger | 67 | 2022 | Independent Director |
William G. Rice | 65 | 2013 | Chairman, President & CEO |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review